Niti Surgical Solutions receives patent certificates for Hand CAC 30 and CAR 31 in Japan and China

NewsGuard 100/100 Score

NiTi Surgical Solutions, an innovative surgical device company, today announced the Japan Patent Office and the Patent Office of China have issued patent certificates that cover two of the company’s products, the Hand CAC™ 30 Compressions Anastomosis Clip applicator and CAR™ 31 Compression Anastomosis Ring. The company’s unique line of products utilizes Nitinol-based elements to press together the ends of resected tissue, enabling natural reconnection and healing of the intestine after removing a section as part of a surgery, such as in colon cancer treatment. The company is commercializing a family of FDA-cleared and CE-marked disposable tissue closure devices.

The Japanese Patent and Trademark Office approved the issuance of patent number 4296151 covering NiTi’s Hand CAC 30. In addition, The Patent Office of China issued patent numbers ZL03812116.6 and ZL03817485.5 covering Hand CAC 30 and CAR 31 respectively. The patents, which were assigned to NiTi by the inventors of the technology, cover the company’s anastomosis products which are based on the novel BioDynamix™ Anastomosis technology and further strengthen the company’s global intellectual property estate and presence in the surgical market.

“We are pleased to strengthen the company’s intellectual property portfolio around its core technology with the issuance of these two patents,” said Itay Itzhaky, chief executive officer of NiTi Surgical Solutions. “Our products are designed to leverage the body’s natural healing process and offer a unique set of benefits for surgeons and their patients. We believe these characteristics, which will extend across our BioDynamix technology platform of products, will support rapid adoption among leading surgeons around the world.”

The Japan patent and one of the China patents cover NiTi’s Hand CAC 30 applicator which is used for side-to-side anastomosis. This sterile, single patient, single-use device is CE-marked and cleared by the FDA. It deploys the Compression Anastomosis Clip (CAC™) during side-to-side and end-to-side anastomoses. The palm-sized applier instrument is designed for colorectal, gastric and upper GI surgeries.

The second China patent for Intratubular Anastomosis Apparatus, is related the CAR 31. CAR 31 also incorporate Nitinol elements and leverages the BioDynamix approach to healing for use in end-to-end compression anastomosis.

NiTi’s line of innovative medical devices for use in compression anastomosis incorporate the company’s novel BioDynamix Anastomosis technology and Nitinol-based elements across the company’s unique line of products in applying consistent compression, without the need for staples, to sections of the intestine after surgery, such as in colon cancer treatment, in order to promote complete and natural healing. In human trials and clinical practice, NiTi’s BioDynamix Anastomosis technology has shown the potential to provide durable anastomosis with encouraging results in the rate of complications, particularly in low cases. The technology has been used in over 7,500 procedures performed globally to-date.

Itzhaky added, "Having commercialized the first major advancement in over 30 years of colorectal surgery with the launch of ColonRing, our anastomosis technology represents a significant breakthrough in the development of non-staple closure devices. We look forward to continuing to bring innovative, game-changing surgical products to the global marketplace.”

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New AI tool 'TORCH' successfully identifies cancer origins in unknown primary cases